Introduction. Inflammation is one of the leading components in the pathogenesis of acute lower limb ischemia (ALLI). Interleukin-18 (IL-18), a pleiotropic proinflammatory cytokine that regulates innate and adaptive immune responses, plays a significant role in the development of chronic inflammation in atherosclerosis, creating the prerequisites for the development of ALLI. Increased IL-18 production causes autoinflammation, destabilization of atherosclerotic plaques, development of thrombosis and ALLI. Objective. To study the contribution of interleukin-18 during ALLI, its relationship with markers of inflammation, lipid metabolism, tissue destruction and endothelial dysfunction. Materials and Methods. 71 patients with ALLI and basic therapy aged 70 (60; 83) years and 15 patients aged 75 (77; 88) years with vasaprostan therapy were examined in the Department of Vascular Surgery of the I. I. Dzhanelidze Research Institute of Emergency Care. The comparison group consisted of volunteers of the same age. On admission to the department before surgery, on days 1 and 10 after reconstructive surgery the following blood levels were examined: cytokines IL-6, IL-10, IL-18, C-reactive protein; tissue damage factors (creatine kinase, myoglobin) and endothelial dysfunction factor (homocysteine), glucose, total protein, and blood lipids. Results. After surgery, an increase in C-reactive protein and inflammatory cytokines, as well as signs of energy deficiency (hyperglycemia, hypopoproteinemia, and hypolipidemia) was observed. An increase in creatine kinase activity, myoglobin and homocysteine levels was more pronounced in deceased patients. The use of vasaprostan reduces inflammatory markerscompared to baseline therapy. Conclusion. IL-18 plays a significant role in the development of inflammation in ALLI. Vasaprostan therapy reduces C-reactive protein levels, inflammatory cytokines, and systemic inflammation and can be recommended for the treatment of ALLI.